Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$2.02	$2.83	$1.61 ▼ $6.88	$363.78M	0.89	4.09 million shs	9.27 million shs
LRMR Larimar Therapeutics	$3.64 -0.1%	$3.92	$2.22 ▼ $6.42	$378.13M	0.83	1.79 million shs	3.30 million shs
PMN Promis Neurosciences	$10.54	$10.76	$6.27 ▼ $39.75	$94.52M	-0.19	19,483 shs	5,848 shs
RGNX REGENXBIO	$7.80	$7.86	$5.45 ▼ $16.19	$403.24M	1.04	1.56 million shs	3.11 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	0.00%	-0.49%	+6.88%	-60.78%	-15.13%
LRMR Larimar Therapeutics	0.00%	+4.84%	+3.06%	-18.98%	+32.77%
PMN Promis Neurosciences	0.00%	+1.84%	-0.57%	-40.11%	-15.68%
RGNX REGENXBIO	0.00%	+17.12%	+30.65%	-3.70%	-8.98%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$2.02	$2.83	$1.61 ▼ $6.88	$363.78M	0.89	4.09 million shs	9.27 million shs
LRMR Larimar Therapeutics	$3.64 -0.1%	$3.92	$2.22 ▼ $6.42	$378.13M	0.83	1.79 million shs	3.30 million shs
PMN Promis Neurosciences	$10.54	$10.76	$6.27 ▼ $39.75	$94.52M	-0.19	19,483 shs	5,848 shs
RGNX REGENXBIO	$7.80	$7.86	$5.45 ▼ $16.19	$403.24M	1.04	1.56 million shs	3.11 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	0.00%	-0.49%	+6.88%	-60.78%	-15.13%
LRMR Larimar Therapeutics	0.00%	+4.84%	+3.06%	-18.98%	+32.77%
PMN Promis Neurosciences	0.00%	+1.84%	-0.57%	-40.11%	-15.68%
RGNX REGENXBIO	0.00%	+17.12%	+30.65%	-3.70%	-8.98%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	2.86	Moderate Buy	$12.91	539.06% Upside
LRMR Larimar Therapeutics	3.09	Buy	$15.29	320.17% Upside
PMN Promis Neurosciences	2.60	Moderate Buy	$26.50	151.42% Upside
RGNX REGENXBIO	2.73	Moderate Buy	$23.55	201.86% Upside

Current Analyst Ratings Breakdown

Latest PMN, RGNX, CMPX, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2026	PMN Promis Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/9/2026	PMN Promis Neurosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/8/2026	RGNX REGENXBIO	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/8/2026	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
6/5/2026	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$30.00 ➝ $26.00
6/4/2026	CMPX Compass Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
6/1/2026	CMPX Compass Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$6.00
5/27/2026	LRMR Larimar Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$9.00
5/20/2026	PMN Promis Neurosciences	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
5/18/2026	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$13.00 ➝ $12.00
5/15/2026	RGNX REGENXBIO	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$16.00

(Data available from 6/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	427.98	N/A	N/A	$1.11 per share	1.82
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$0.94 per share	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	($0.58) per share	N/A
RGNX REGENXBIO	$87.82M	4.59	N/A	N/A	$2.03 per share	3.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$66.49M	-$0.41	N/A	N/A	N/A	N/A	-39.75%	-35.29%	8/10/2026 (Estimated)
LRMR Larimar Therapeutics	-$165.67M	-$2.06	N/A	N/A	N/A	N/A	-134.14%	-96.00%	8/13/2026 (Estimated)
PMN Promis Neurosciences	-$39.72M	-$14.51	N/A	N/A	N/A	N/A	-237.99%	-151.04%	8/12/2026 (Estimated)
RGNX REGENXBIO	-$193.88M	-$5.60	N/A	N/A	N/A	-330.23%	-232.50%	-61.02%	8/6/2026 (Estimated)

Latest PMN, RGNX, CMPX, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2026	Q1 2026	LRMR Larimar Therapeutics	-$0.53	-$0.31	+$0.22	-$0.31	N/A	N/A
5/14/2026	Q1 2026	RGNX REGENXBIO	-$1.36	-$1.72	-$0.36	-$1.72	$25.84 million	$6.39 million
5/12/2026	Q1 2026	PMN Promis Neurosciences	-$1.06	-$1.26	-$0.20	-$1.26	N/A	N/A
5/5/2026	Q1 2026	CMPX Compass Therapeutics	-$0.10	-$0.10	N/A	-$0.10	($0.82) million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	19.04	19.04
LRMR Larimar Therapeutics	N/A	4.29	4.29
PMN Promis Neurosciences	N/A	9.92	9.92
RGNX REGENXBIO	N/A	2.62	2.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
LRMR Larimar Therapeutics	91.92%
PMN Promis Neurosciences	50.13%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	18.70%
LRMR Larimar Therapeutics	4.50%
PMN Promis Neurosciences	1.50%
RGNX REGENXBIO	14.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	180.09 million	146.41 million	Not Optionable
LRMR Larimar Therapeutics	30	103.88 million	99.21 million	Optionable
PMN Promis Neurosciences	5	8.97 million	8.83 million	Not Optionable
RGNX REGENXBIO	370	51.70 million	44.35 million	Optionable

PMN, RGNX, CMPX, and LRMR Headlines

Recent News About These Companies

REGENXBIO, Replimune among gainers after FDA U-turn on UniQure

June 17 at 3:32 PM | msn.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Rating of "Moderate Buy" from Analysts

June 15, 2026 | americanbankingnews.com

Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM)

June 6, 2026 | theglobeandmail.com

How The REGENXBIO (RGNX) Investment Story Is Evolving Without New Analyst Commentary

June 2, 2026 | finance.yahoo.com

REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

May 22, 2026 | seekingalpha.com

REGENXBIO to Participate in Upcoming Investor Conferences

May 18, 2026 | prnewswire.com

StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate

May 18, 2026 | genengnews.comG

Regenxbio (RGNX) Q1 2026 Earnings Transcript

May 18, 2026 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: RegenXBio (RGNX), Align Tech (ALGN) and Keros Therapeutics (KROS)

May 17, 2026 | theglobeandmail.com

Regenxbio: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results

May 17, 2026 | seekingalpha.com

Regenxbio: Q1 Earnings Snapshot

May 15, 2026 | stamfordadvocate.comS

RGNX stock on track for worst day ever as big Q1 loss, cash concerns eclipse Duchenne trial success

May 15, 2026 | msn.com

REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript

May 14, 2026 | seekingalpha.com

Regenxbio's muscle disorder therapy meets main goal in late-stage study

May 14, 2026 | msn.com

Regenxbio slides after late-stage trial data for Duchenne therapy

May 14, 2026 | seekingalpha.com

Regenxbio Shares Rise After Positive Duchenne Trial Results

May 14, 2026 | finance.yahoo.com

Regenxbio Inc (RGNX) Q1 2026 Earnings Call Highlights: Promising RGX-202 Results and Path to ...

May 14, 2026 | finance.yahoo.com

REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval

May 14, 2026 | benzinga.com

Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates

May 14, 2026 | zacks.com

Insider Selling: REGENXBIO (NASDAQ:RGNX) Insider Sells 15,309 Shares of Stock

May 14, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN, RGNX, CMPX, and LRMR Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$2.02 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$2.04 +0.02 (+1.24%)

As of 06/18/2026 07:40 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Larimar Therapeutics NASDAQ:LRMR

$3.64 0.00 (-0.05%)

Closing price 06/18/2026 03:59 PM Eastern

Extended Trading

$3.54 -0.09 (-2.56%)

As of 06/18/2026 07:38 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Promis Neurosciences NASDAQ:PMN

$10.54 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$10.63 +0.09 (+0.85%)

As of 06/18/2026 07:05 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

REGENXBIO NASDAQ:RGNX

$7.80 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$7.95 +0.15 (+1.95%)

As of 06/18/2026 07:55 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PMN, RGNX, CMPX, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PMN, RGNX, CMPX, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PMN, RGNX, CMPX, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN, RGNX, CMPX, and LRMR Company Descriptions

Compass Therapeutics NASDAQ:CMPX

Larimar Therapeutics NASDAQ:LRMR

Promis Neurosciences NASDAQ:PMN

REGENXBIO NASDAQ:RGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PMN, RGNX, CMPX, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PMN, RGNX, CMPX, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PMN, RGNX, CMPX, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMN, RGNX, CMPX, and LRMR Company Descriptions

Compass Therapeutics NASDAQ:CMPX

Larimar Therapeutics NASDAQ:LRMR

Promis Neurosciences NASDAQ:PMN

REGENXBIO NASDAQ:RGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools